Company Description
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain.
Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
The company also develops three product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel - SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4%, a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules), a novel low-dose delayed-release naltrexone hydrochloride, which has completed phase 1 trials for the treatment of fibromyalgia.
It has an agreement with Oishi and Itochu to develop lidocaine tape products, including ZTlido and SP-103; and Lifecore Biomedical, LLC for clinical trial material manufacturing and development services for SEMDEXA.
Scilex Holding Company is headquartered in Palo Alto, California.
| Country | United States |
| Founded | 2011 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 115 |
| CEO | Jaisim Shah |
Contact Details
Address: 960 San Antonio Road Palo Alto, California 94303 United States | |
| Phone | 650 516 4310 |
| Website | scilexholding.com |
Stock Details
| Ticker Symbol | SCLX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001820190 |
| CUSIP Number | 80880W106 |
| ISIN Number | US80880W2052 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jaisim Shah | President, Chief Executive Officer and Director |
| Dr. Henry H. Ji Ph.D. | Executive Chairman |
| Stephen Ma | Senior Vice President, Chief Financial Officer and Corporate Secretary |
| Dr. Suketu D. Desai Ph.D. | Chief Technology Officer and Senior Vice President |
| Steven F. Lincoln J.D. | General Counsel and Chief Compliance Officer |
| Sumant Rajendran | Executive Director of Marketing |
| Suresh K. Khemani | Senior Vice President and Chief Commercial Officer |
| Dr. Dmitri V. Lissin M.D. | Senior Vice President and Chief Medical Officer |
| Gigi DeGuzman | Senior Executive Director and Chief of Staff |
| Dr. Elaine K Chan Pharm.D. | Executive Director and Head of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 24, 2025 | 424B3 | Prospectus |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 4, 2025 | 8-K | Current Report |
| May 16, 2025 | ARS | Filing |
| May 16, 2025 | DEF 14A | Other definitive proxy statements |
| May 15, 2025 | 424B3 | Prospectus |
| May 15, 2025 | 424B3 | Prospectus |